StreetInsider.com News Articles

RedHill initiates enforcement of $10.9 million judgment in Korea

Mon, 08 Jun 2026 07:01:11 -0400

RedHill Biopharma Ltd. (NASDAQ: RDHL) has commenced recognition and enforcement proceedings in Korea for a New York Supreme Court judgment totaling approximately $10.9 million against Kukbo Co. Ltd., according to a company statement.

The judgment became final in November 2025 after the New York Supreme Court ruled in favor of RedHill. An additional award for legal fees and expenses became final in March 2026 when Kukbo failed to perfect its appeal by the applicable deadline. No further appeals are permitted for either judgment.

The total award consists of approximately $8.9 million for the main judgment and approximately $1.95 million for legal fees

RedHill initiates enforcement of $10.9 million judgment in Korea

Mon, 08 Jun 2026 07:01:11 -0400

The total award consists of approximately $8.9 million for the main judgment and approximately $1.95 million for legal fees

RedHill Launches Enforcement of $11 Million New York Supreme Court Final Judgment Against Kukbo

Mon, 08 Jun 2026 07:00:00 -0400

RALEIGH, N.C. and TEL-AVIV, Israel, June 8, 2026 /PRNewswire/ -- RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has commenced recognition and enforcement proceedings in Korea in respect of the New York Supreme Court's final judgment in favor of RedHill against Kukbo Co. Ltd ("Kukbo"), totaling approximately $10.9 million, and that Kukbo has now been served in those proceedings.

Positive Results from Phase 2a Clinical Trial

Study met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumors

Trial revealed promising efficacy signals with fewer deaths due to metastasis in the ifetroban arm, than in the placebo arm (p=0.037)

Results support development of ifetroban as a candidate for metastasis prevention

NASHVILLE, Tenn., June 2, 2026 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company focused on developing new products for rare diseases, and Vanderbilt Health today announce data from a Phase 2a clinical trial of ifetroban to prevent metastasis

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

Tue, 02 Jun 2026 09:05:00 -0400

Positive Results from Phase 2a Clinical Trial

Study met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumors

Trial revealed promising efficacy signals with fewer deaths due to metastasis in the ifetroban arm, than in the placebo arm (p=0.037)

Results support development of ifetroban as a candidate for metastasis prevention

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

Tue, 02 Jun 2026 09:05:00 -0400

Positive Results from Phase 2a Clinical Trial

Study met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumors

Trial revealed promising efficacy signals with fewer deaths due to metastasis in the ifetroban arm, than in the placebo arm (p=0.037)

Results support development of ifetroban as a candidate for metastasis prevention

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

Tue, 02 Jun 2026 09:05:00 -0400

Positive Results from Phase 2a Clinical Trial

Study met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumors

Trial revealed promising efficacy signals with fewer deaths due to metastasis in the ifetroban arm, than in the placebo arm (p=0.037)

Results support development of ifetroban as a candidate for metastasis prevention

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

Tue, 02 Jun 2026 09:05:00 -0400

Positive Results from Phase 2a Clinical Trial

Study met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumors

Trial revealed promising efficacy signals with fewer deaths due to metastasis in the ifetroban arm, than in the placebo arm (p=0.037)

Results support development of ifetroban as a candidate for metastasis prevention

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

Tue, 02 Jun 2026 09:05:00 -0400

Positive Results from Phase 2a Clinical Trial

Study met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumors

Trial revealed promising efficacy signals with fewer deaths due to metastasis in the ifetroban arm, than in the placebo arm (p=0.037)

Results support development of ifetroban as a candidate for metastasis prevention

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

Tue, 02 Jun 2026 09:05:00 -0400

Positive Results from Phase 2a Clinical Trial

Study met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumors

Trial revealed promising efficacy signals with fewer deaths due to metastasis in the ifetroban arm, than in the placebo arm (p=0.037)

Results support development of ifetroban as a candidate for metastasis prevention

Cumberland Pharmaceuticals and Vanderbilt Health Announce Potential New Therapy to Prevent Cancer Metastasis

Tue, 02 Jun 2026 09:05:00 -0400

Positive Results from Phase 2a Clinical Trial

Study met its primary endpoint demonstrating safety and tolerability of ifetroban in patients with high-risk solid tumors

Trial revealed promising efficacy signals with fewer deaths due to metastasis in the ifetroban arm, than in the placebo arm (p=0.037)

Results support development of ifetroban as a candidate for metastasis prevention

RedHill explores opaganib for ebola outbreak response

Tue, 02 Jun 2026 08:00:56 -0400

RedHill Biopharma Ltd. (NASDAQ: RDHL) announced it is discussing potential collaborations to advance its investigational drug opaganib for Ebola virus disease treatment, including with the World Health Organization's SOLIDARITY CORE clinical trial platform.

The discussions come amid an ongoing Ebola outbreak involving the rare Bundibugyo ebolavirus sub-type, for which no approved medications or vaccines exist. The WHO has indicated the current outbreak is outpacing response efforts.

Opaganib demonstrated a 70.2% mortality reduction when added to standard care in a Phase 3 COVID-19 trial, according to data published in Microorganisms. The treatment group showed 6.98% mortality compared to 23.4% in the placebo group